Vittoria Biotherapeutics, Inc.

Overview

Vittoria Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to address the limitations of current cell therapy approaches, especially in treating difficult-to-treat diseases in oncology and autoimmune disorders.

Central to its work is the proprietary Senza5™ platform technology, which enhances the effectiveness of engineered T cells by modulating CD5 signaling. The platform features a rapid five-day manufacturing process aimed at improving production efficiency and maximizing T cell stemness, durability, and potency. The company’s lead product candidate, VIPER-101, is undergoing Phase 1 clinical trials for recurrent nodal peripheral T-cell lymphoma. Its pipeline includes therapies targeting solid tumors and autoimmune diseases, demonstrating a commitment to transforming patient treatment options and actively advancing clinical research.

Basic Information

Contact Details

• Phone: +1 215-600-1380
• Website: vittoriabio.com
• LinkedIn: linkedin.com/company/vittoriabio

Key Focus Areas & Initiatives

• CAR T-cell therapy for oncology and autoimmune disorders
• Senza5™ platform technology for engineered T cells
• Rapid five-day cell manufacturing process
• VIPER-101 clinical trials (autologous CAR T-cell therapy)
• CD5 signaling modulation in cell therapy
• Therapies targeting solid tumors and autoimmune diseases
• T-cell stemness, potency, and durability enhancement
• Clinical-stage immunotherapy development
• Pipeline for challenging cancers and immune conditions
• Active recruitment in clinical trials

Technologies Used

• Google Analytics
• Google Tag Manager
• Gravity Forms
• Microsoft Office 365
• Mobile Friendly
• Outlook
• WordPress.org

Affiliated Organizations & Regional Branches